patisiran
Sign in to saveAlso known as Onpattro
Patisiran, sold under the brand name Onpattro, is a medication used for the treatment of polyneuropathy in people with hereditary transthyretin-mediated amyloidosis, a fatal rare disease that is estimated to affect 50,000 people worldwide.
In the Vinony graph
Within Vinony's link graph, patisiran is referenced by 37 other articles, and connects out to small interfering RNA, medication and stroke.
Vinony files it under Biopharmaceuticals, Chemical pages without ChemSpiderID and Chemicals using indexlabels.
Its subject is documented across 12 Wikipedia language editions.
Key facts
- Drug.image
- Patisiran sodium.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 375
- Drug.tradename
- Onpattro
- Drug.DailyMedID
- Patisiran
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- N07
- Drug.ATC_suffix
- XX12
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.index2_label
- as salt
- Drug.CAS_number
- 1420706-45-1
- Drug.DrugBank
- DB14582
- Drug.UNII
- 50FKX8CB2Y
- Drug.KEGG
- D11116
via Wikipedia infobox
Wikidata facts
- Mass
- 13424.346
- Has use
- medication
Show 4 more facts
- Commons category
- Patisiran
- subject has role
- active ingredient
- chemical formula
- C₄₁₂H₅₂₀N₁₄₈O₂₉₀P₄₀
- medical condition treated
- amyloidosis
via Wikidata · CC0
~2 min read
Encyclopedic overview
5 sectionsContents
- History
- Formulation
- Society and culture
- Economics
- References
Patisiran, sold under the brand name Onpattro, is a medication used for the treatment of polyneuropathy in people with hereditary transthyretin-mediated amyloidosis, a fatal rare disease that is estimated to affect 50,000 people worldwide.
It is the first small interfering RNA-based drug approved by the U.S. Food and Drug Administration (FDA) and the first drug approved by the FDA to treat this condition. It is a gene silencing drug that interferes with the production of an abnormal form of transthyretin. Patisiran utilizes a novel approach to target and reduce production of the TTR protein in the liver via the RNAi pathway.
Excerpted from Wikipedia’s “patisiran” article, available under the CC BY-SA 4.0 licence.